Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • Big pharma
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • Big pharma
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

New products alone are not enough. Pharma can do more to halt COVID-19.

The COVID-19 epidemic will hit the most vulnerable people hardest. In this Viewpoint, Research Programme Manager Danny Edwards explains that the pharmaceutical industry has a responsibility to do more than develop new vaccines and medicines – companies must also help achieve fair, global access to new products.

Date

14 April 2020

Download this publication

The pharmaceutical industry is now working toward new treatments and vaccines targeting COVID-19. This is one half of the equation. When those new products leave the pipeline, ensuring they are made widely accessible will be the central issue. People in more vulnerable countries and communities must not be left behind. 

Early and ambitious action by companies sets the standard for others. To stimulate pharmaceutical companies to act now, the Foundation has also compiled a non-exhaustive list of positive actions already being taken by companies, which is included in the PDF download.


Claudia Martínez

Research Programme Manager

Get in touch

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved